Neuropathy / diabetic peripheral neuropathy

Red light therapy for neuropathy

Early evidence on photobiomodulation for diabetic peripheral neuropathy symptoms and nerve-related outcomes.

Study count

The cited systematic review included eight randomized and non-randomized studies.

Evidence grade

low

Panel relevance

partially-replicable

Bottom line

Neuropathy content should be cautious and medical-context-first, especially for diabetes-related neuropathy.

Consensus: Evidence is early and suggests possible benefit for diabetic peripheral neuropathy pain and nerve conduction, but certainty is low.

The review reported improvements in neuropathic pain and nerve conduction velocity across included studies.
The review also described reductions in plantar pressure distribution, a risk factor related to diabetic foot ulcers.
Because non-randomized studies were included, the category should remain low-certainty.

Wavelengths	Not settled nm
Irradiance	Not settled
Fluence	Not settled
Session time	Varied by study.
Frequency	Varied by study.
Duration	Varied by study.
Timing	No strong consensus.
Treatment area	Feet or lower limbs in diabetic peripheral neuropathy studies.
Device types	Photobiomodulation therapy devices.
Notes	Evidence includes randomized and non-randomized designs.

No general panel dosage can be extracted responsibly from the cited review alone.
Peripheral neuropathy protocols should be separated by cause rather than treated as one category.
Diabetes-related neuropathy requires medical management beyond symptom relief.

Neuropathy has many causes and may signal serious disease.
Reduced sensation increases burn and injury risk with any device used on feet or legs.
Diabetes care should not be delayed or replaced by PBM.

systematic-review

Korada HY, Arora E, Maiya GA, et al. Current Diabetes Reviews. 2023.

A systematic review found PBM studies reporting improvements in neuropathic pain, nerve conduction, and plantar pressure distribution.

Last reviewed: 2026-06-15